Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agatha Labrinidis

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
International Journal of Cancer|March 22, 2006
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAILLisa M Butler, Vasilios Liapis, Stelios Bouralexis, et al.
Cancer|February 3, 2011
RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic modelJonathan C M Clark, Toru Akiyama, David M Thomas, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 2, 2009
Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone lossPeter Diamond, Agatha Labrinidis, Sally K Martin, et al.
Anticancer Research|December 16, 2014
Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs)Irene Zinonos, Agatha Labrinidis, Vasilios Liapis, et al.
Cancer Letters|December 3, 2014
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcomaVasilios Liapis, Agatha Labrinidis, Irene Zinonos, et al.
Cancer Medicine|January 11, 2016
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine modelsVasilios Liapis, Irene Zinonos, Agatha Labrinidis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaAgatha Labrinidis, Peter Diamond, Sally Martin, et al.
Nutrients|March 6, 2021
Effect of Selenium and Iodine on Oxidative Stress in the First Trimester Human Placenta ExplantsNahal Habibi, Agatha Labrinidis, Shalem Yiner-Lee Leemaqz, et al.
International Journal of Oncology|May 29, 2014
Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancerIrene Zinonos, Ke-Wang Luo, Agatha Labrinidis, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Cancer|March 22, 2006
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAILLisa M Butler, Vasilios Liapis, Stelios Bouralexis, et al.
Cancer|February 3, 2011
RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic modelJonathan C M Clark, Toru Akiyama, David M Thomas, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 2, 2009
Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone lossPeter Diamond, Agatha Labrinidis, Sally K Martin, et al.
Anticancer Research|December 16, 2014
Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs)Irene Zinonos, Agatha Labrinidis, Vasilios Liapis, et al.
Cancer Letters|December 3, 2014
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcomaVasilios Liapis, Agatha Labrinidis, Irene Zinonos, et al.
Cancer Medicine|January 11, 2016
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine modelsVasilios Liapis, Irene Zinonos, Agatha Labrinidis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaAgatha Labrinidis, Peter Diamond, Sally Martin, et al.
Nutrients|March 6, 2021
Effect of Selenium and Iodine on Oxidative Stress in the First Trimester Human Placenta ExplantsNahal Habibi, Agatha Labrinidis, Shalem Yiner-Lee Leemaqz, et al.
International Journal of Oncology|May 29, 2014
Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancerIrene Zinonos, Ke-Wang Luo, Agatha Labrinidis, et al.
Pageof 2